685 related articles for article (PubMed ID: 26956246)
1. Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.
Toll L; Bruchas MR; Calo' G; Cox BM; Zaveri NT
Pharmacol Rev; 2016 Apr; 68(2):419-57. PubMed ID: 26956246
[TBL] [Abstract][Full Text] [Related]
2. Cellular mechanisms of nociceptin/orphanin FQ (N/OFQ) peptide (NOP) receptor regulation and heterologous regulation by N/OFQ.
Donica CL; Awwad HO; Thakker DR; Standifer KM
Mol Pharmacol; 2013 May; 83(5):907-18. PubMed ID: 23395957
[TBL] [Abstract][Full Text] [Related]
3. The biology of Nociceptin/Orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence.
Witkin JM; Statnick MA; Rorick-Kehn LM; Pintar JE; Ansonoff M; Chen Y; Tucker RC; Ciccocioppo R
Pharmacol Ther; 2014 Mar; 141(3):283-99. PubMed ID: 24189487
[TBL] [Abstract][Full Text] [Related]
4. Structure of the nociceptin/orphanin FQ receptor in complex with a peptide mimetic.
Thompson AA; Liu W; Chun E; Katritch V; Wu H; Vardy E; Huang XP; Trapella C; Guerrini R; Calo G; Roth BL; Cherezov V; Stevens RC
Nature; 2012 May; 485(7398):395-9. PubMed ID: 22596163
[TBL] [Abstract][Full Text] [Related]
5. Potential of Nociceptin/Orphanin FQ Peptide Analogs for Drug Development.
Wtorek K; Janecka A
Chem Biodivers; 2021 Jan; 18(1):e2000871. PubMed ID: 33351271
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological characterization of nociceptin/orphanin FQ receptors, a novel opioid receptor family, in the midbrain periaqueductal gray.
Chiou LC; Fan SH; Chuang KC; Liao YY; Lee SZ
Ann N Y Acad Sci; 2004 Oct; 1025():398-403. PubMed ID: 15542742
[TBL] [Abstract][Full Text] [Related]
7. Nociceptin/orphanin FQ and its receptor--potential targets for pain therapy?
Zeilhofer HU; Calò G
J Pharmacol Exp Ther; 2003 Aug; 306(2):423-9. PubMed ID: 12721334
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological activity of small peptides as NOP and opioid receptors' ligands: view on current developments.
Naydenova E; Todorov P; Zamfirova R
Vitam Horm; 2015; 97():123-46. PubMed ID: 25677770
[TBL] [Abstract][Full Text] [Related]
9. Quantitative study of [Tyr10]nociceptin/orphanin FQ (1-11) at NOP receptors in rat periaqueductal gray and expressed NOP receptors in HEK293 cells.
Liao YY; Lee CW; Ho IK; Chiou LC
Life Sci; 2012 Feb; 90(7-8):306-12. PubMed ID: 22213115
[TBL] [Abstract][Full Text] [Related]
10. Central N/OFQ-NOP Receptor System in Pain Modulation.
Kiguchi N; Ding H; Ko MC
Adv Pharmacol; 2016; 75():217-43. PubMed ID: 26920014
[TBL] [Abstract][Full Text] [Related]
11. NOP Ligands for the Treatment of Anxiety and Mood Disorders.
Gavioli EC; Holanda VAD; Ruzza C
Handb Exp Pharmacol; 2019; 254():233-257. PubMed ID: 30535941
[TBL] [Abstract][Full Text] [Related]
12. Nociceptin/orphanin FQ peptide receptors: pharmacology and clinical implications.
Chiou LC; Liao YY; Fan PC; Kuo PH; Wang CH; Riemer C; Prinssen EP
Curr Drug Targets; 2007 Jan; 8(1):117-35. PubMed ID: 17266536
[TBL] [Abstract][Full Text] [Related]
13. Nociceptin/orphanin FQ receptor antagonists as innovative antidepressant drugs.
Gavioli EC; Calo' G
Pharmacol Ther; 2013 Oct; 140(1):10-25. PubMed ID: 23711793
[TBL] [Abstract][Full Text] [Related]
14. Role of Nociceptin/Orphanin FQ-NOP Receptor System in the Regulation of Stress-Related Disorders.
Ubaldi M; Cannella N; Borruto AM; Petrella M; Micioni Di Bonaventura MV; Soverchia L; Stopponi S; Weiss F; Cifani C; Ciccocioppo R
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884757
[TBL] [Abstract][Full Text] [Related]
15. Nociceptin/orphanin FQ-NOP receptor system in inflammatory and immune-mediated diseases.
Gavioli EC; de Medeiros IU; Monteiro MC; Calo G; Romão PR
Vitam Horm; 2015; 97():241-66. PubMed ID: 25677775
[TBL] [Abstract][Full Text] [Related]
16. Effects of spinally administered bifunctional nociceptin/orphanin FQ peptide receptor/μ-opioid receptor ligands in mouse models of neuropathic and inflammatory pain.
Sukhtankar DD; Zaveri NT; Husbands SM; Ko MC
J Pharmacol Exp Ther; 2013 Jul; 346(1):11-22. PubMed ID: 23652222
[TBL] [Abstract][Full Text] [Related]
17. Characterisation of the Novel Mixed Mu-NOP Peptide Ligand Dermorphin-N/OFQ (DeNo).
Bird MF; Cerlesi MC; Brown M; Malfacini D; Vezzi V; Molinari P; Micheli L; Di Cesare Mannelli L; Ghelardini C; Guerrini R; Calò G; Lambert DG
PLoS One; 2016; 11(6):e0156897. PubMed ID: 27272042
[TBL] [Abstract][Full Text] [Related]
18. Designing bifunctional NOP receptor-mu opioid receptor ligands from NOP-receptor selective scaffolds. Part II.
Journigan VB; Polgar WE; Khroyan TV; Zaveri NT
Bioorg Med Chem; 2014 Apr; 22(8):2508-16. PubMed ID: 24657054
[TBL] [Abstract][Full Text] [Related]
19. [Nociceptin/orphanin FQ (N/OFQ)--the opioid, antiopioid or neuromodulator?].
Kotlińska J; Rafalski P
Postepy Hig Med Dosw (Online); 2004 Apr; 58():209-15. PubMed ID: 15114256
[TBL] [Abstract][Full Text] [Related]
20. Differential In Vitro Pharmacological Profiles of Structurally Diverse Nociceptin Receptor Agonists in Activating G Protein and Beta-Arrestin Signaling at the Human Nociceptin Opioid Receptor.
Lu JJ; Polgar WE; Mann A; Dasgupta P; Schulz S; Zaveri NT
Mol Pharmacol; 2021 Jul; 100(1):7-18. PubMed ID: 33958480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
